ETHRIS
Corporate brand
UnclaimedEthris is a Planegg-based mRNA therapeutics and vaccines company developing proprietary SNIM®RNA and SNaP LNP® delivery platforms.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Ethris, based in Planegg near Munich, was founded by Dr. Carsten Rudolph and Prof. Dr. Christian Plank to establish messenger RNA (mRNA) as a new drug modality. The company pioneers next-generation mRNA therapeutics and vaccines using its proprietary SNIM®RNA and SNaP LNP® platforms, which enable thermostable, multi-route, multi-cargo delivery. Its primary focus is first-in-class mRNA-based therapeutics to prevent virus-induced exacerbations in asthma and COPD, with lead candidate ETH47, and it also pursues mucosal vaccines and protein replacement candidates with an initial focus on rare genetic disorders such as primary ciliary dyskinesia (PCD). Ethris states its goal is to become the leader in inhaled mRNA therapeutics and is seeking strategic partnerships and licensing arrangements.
History
Ethris, based in Planegg near Munich, was founded by Dr. Carsten Rudolph and Prof. Dr. Christian Plank to establish messenger RNA (mRNA) as a new drug modality. The company describes itself as an mRNA pioneer applying its proprietary SNIM® RNA and SNaP LNP® formulation and delivery platforms to provide versatile, multi-route, multi-cargo delivery options that drive drug candidates through proof-of-concept and into the clinic. It states it is leveraging a first-mover advantage through differentiated nebulization technology for inhaled delivery of mRNA therapeutics directly to the upper and lower respiratory tract.
Products and positioning
Ethris' goal is to become the leader in inhaled mRNA therapeutics.
ETH47
Lead candidate, a novel mRNA-based therapeutic that activates the body's innate immune defense against respiratory viruses.
SNIM®RNA
Proprietary RNA platform technology.
SNaP LNP®
Proprietary lipid nanoparticle delivery platform technology.
Recent events
Reported
Ethris receives Top 3 innovation award for ETH47[5]
Ethris said its COVID-19 therapeutic candidate ETH47 received the “Most Innovative Product Top 3” award in the Leap Innovations category at the Pharma Trend Image Innovation Awards 2021. The prize was presented to Ethris CEO Dr. Carsten Rudolph at a ceremony in Munich on September 14, 2021.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ethris · Editorial policy · How profiles are compiled